ALISO VIEJO, Calif., Nov. 9 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it is scheduled to make presentations at two upcoming investor conferences in New York City.
The first presentation will be made at the Lazard Capital Markets Sixth Annual Healthcare Conference at 1:40 pm EST on Tuesday, November 17. The conference will be held at the St. Regis Hotel November 17-18.
The second presentation will be made at the 21st Annual Piper Jaffray Health Care Conference at 10:30 am EST on Wednesday, December 2. The conference will be held at the New York Palace Hotel December 1-2.
Live webcasts of the Company's presentations at the conferences will be available via a link provided at http://www.clarientinc.com/investor. Archived replays of the presentations will also be available shortly after the presentation time for a period of at least 60 days.
Clarient combines innovative diagnostic technologies with world-class pathology expertise to assess and characterize cancer. Clarient's mission is to become the leader in cancer diagnostics by collaborating with the healthcare community to translate cancer research and development into better patient care. Clarient's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies. The rise of individualized medicine has created the need for a centralized resource which provides leading oncology diagnostic technologies, such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory, which provides the most advanced oncology testing and diagnostic services available. Resulting diagnostic reports and analyses are made available to customers through Clarient's Internet-based portal, PATHSiTE(TM). Clarient also plans to develop and market new, proprietary "companion" diagnostic markers for therapeutics in breast, prostate, lung and colon cancers, and leukemia/lymphoma. www.clarientinc.com
Investor Contact: Matt Clawson Allen & Caron Inc (949) 474-4300 firstname.lastname@example.org
SOURCE Clarient, Inc.
|SOURCE Clarient, Inc.|
Copyright©2009 PR Newswire.
All rights reserved